TAO Synergies (TAOX) Non Operating Income (2021 - 2026)
TAO Synergies' (TAOX) quarterly Non Operating Income came in at -$7.7 million in Q2 2026, up 46.62% on a YoY basis from -$5.3 million in Q2 2025, and down 238.72% quarter-over-quarter from $5.6 million in Q1 2026.
Analysis
TAO Synergies (TAOX) Non Operating Income (2021 - 2026) Analysis & Trends
TAO Synergies (TAOX) has reported Non Operating Income for 6 consecutive years, with -$7.7 million the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Non Operating Income rose 46.62% year-over-year to -$7.7 million; the trailing twelve-month figure through Jun 2026 stood at -$8.8 million (up 57.54% YoY), and the FY2025 full-year result was -$19.7 million, down 230.5% from the prior year.
- Non Operating Income declined to -$7.7 million in Q2 2026 per TAOX's latest filing, from $5.6 million in the prior quarter.
- Across five years, Non Operating Income topped out at $10.4 million in Q4 2022 and bottomed at -$14.5 million in Q2 2025.
- Historically, Non Operating Income has averaged -$831627.4 across 5 years, with a median of $92608.5 in 2022.
- The widest YoY moves for Non Operating Income: up 26150.69% in 2023, down 5189.67% in 2023.
- Over 5 years, Non Operating Income stood at $10.4 million in 2022, then plunged by 89.04% to $1.1 million in 2023, then tumbled by 450.77% to -$4.0 million in 2024, then slipped by 13.91% to -$4.5 million in 2025, then tumbled by 70.23% to -$7.7 million in 2026.
- According to Business Quant data, Non Operating Income over the past three periods registered -$7.7 million, $5.6 million, and -$4.5 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 212.35 Bn | 198.36 Bn | 7.24 Bn | -73.00 Mn |
| 2 | Gilead Sciences | 181.19 Bn | 178.01 Bn | 6.22 Bn | 387.00 Mn |
| 3 | Vertex Pharmaceuticals | 132.48 Bn | 124.62 Bn | 2.84 Bn | - |
| 4 | Regeneron Pharmaceuticals | 82.59 Bn | 74.60 Bn | 3.93 Bn | 234.30 Mn |
| 5 | Argenx Se | 61.45 Bn | 56.27 Bn | 1.37 Bn | - |
| 6 | Moderna | 54.89 Bn | 49.75 Bn | 52.00 Mn | - |
| 7 | Alnylam Pharmaceuticals | 34.21 Bn | 30.90 Bn | 992.69 Mn | -53.64 Mn |
| 8 | Biogen | 31.38 Bn | 30.10 Bn | 1.96 Bn | - |
| 9 | Roivant Sciences | 29.81 Bn | 29.81 Bn | 1.16 Mn | - |
| 10 | TAO Synergies | 30.41 Mn | 30.41 Mn | - | -7.73 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -7.73 Mn |
| Mar 31, 2026 | 5.57 Mn |
| Dec 31, 2025 | -4.54 Mn |
| Sep 30, 2025 | -2.12 Mn |
| Jun 30, 2025 | -14.48 Mn |
| Mar 31, 2025 | 1.45 Mn |
| Dec 31, 2024 | -3.99 Mn |
| Sep 30, 2024 | -3.76 Mn |
| Jun 30, 2024 | 307,658.00 |
| Mar 31, 2024 | 1.48 Mn |
| Dec 31, 2023 | 1.14 Mn |
| Sep 30, 2023 | 2.19 Mn |
| Jun 30, 2023 | -2.26 Mn |
| Mar 31, 2023 | 1.21 Mn |
| Dec 31, 2022 | 10.37 Mn |
| Sep 30, 2022 | 140,730.00 |
| Jun 30, 2022 | 44,487.00 |
| Mar 31, 2022 | 4,610.00 |
| Mar 31, 2021 | 816.00 |